Incannex wins approval of overseas findings, secures A$5.1 million R&D tax refund
IXHL•R&D tax refund and funding update
Incannex received A$5.1 million from Australia’s R&D Tax Incentive Program following approval of overseas findings for FY25.
Total 2026 proceeds under the program reached more than A$11.2 million in non-dilutive funding.
The cash inflow supports clinical development programs, including IHL-42X and PSX-001.
Related News
IBM, Together AI sign $240 million multi-year deal to scale open-source AI inference on IBM Cloud
IBM•
Phillips 66, Kinder Morgan, HF Sinclair approve $5 billion Western Gateway project
PSX•
